Sarepta Therapeutics Inc (SRPT)

Feb 21, 2025

Sarepta Therapeutics (SRPT) Projected to Announce Quarterly Earnings on Wednesday - MarketBeat

Feb 21, 2025

Feb 21, 2025

Rhumbline Advisers Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Feb 21, 2025

Feb 20, 2025

AlphaCentric Advisors LLC Lowers Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Feb 20, 2025

Feb 20, 2025

Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now? - Insider Monkey

Feb 20, 2025

Feb 20, 2025

15 Best Fast Growth Stocks To Buy Right Now - Insider Monkey

Feb 20, 2025

Feb 20, 2025

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Feb 20, 2025

Feb 19, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Hits New 52-Week LowHere's Why - MarketBeat

Feb 19, 2025

Feb 19, 2025

Van ECK Associates Corp Raises Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Feb 19, 2025

Feb 19, 2025

Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here? - Benzinga

Feb 19, 2025

Feb 19, 2025

Sarepta Therapeutics Closes $600M in Senior Secured Revolving Credit Facility - citybiz

Feb 19, 2025

Feb 19, 2025

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Peregrine Capital Management LLC - MarketBeat

Feb 19, 2025

Feb 19, 2025

Allspring Global Investments Holdings LLC Acquires 84,926 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Feb 19, 2025

Feb 19, 2025

Pfizer’s gene-therapy trial failure boosts Sarepta’s stock - MSN

Feb 19, 2025

Feb 18, 2025

SRPT Quantitative Stock Analysis - Nasdaq

Feb 18, 2025

Feb 18, 2025

Solid says early data suggest ‘differentiated’ Duchenne gene therapy - BioPharma Dive

Feb 18, 2025

Feb 18, 2025

Sarepta stock touches 52-week low at $101.32 amid market challenges - Investing.com

Feb 18, 2025

Feb 18, 2025

Braun Stacey Associates Inc. Sells 2,990 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Feb 18, 2025

Feb 18, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright - MarketBeat

Feb 18, 2025

Feb 18, 2025

Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround - MSN

Feb 18, 2025

Feb 18, 2025

Banque Pictet & Cie SA Has $5.35 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Feb 18, 2025

Feb 16, 2025

Fiera Capital Corp Sells 9,667 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Feb 16, 2025

Feb 15, 2025

Arrowhead and Sarepta close $500 million licensing deal - MSN

Feb 15, 2025

Feb 15, 2025

Sarepta closes on $600M revolving credit facility - MSN

Feb 15, 2025

Feb 15, 2025

Sovran Advisors LLC Invests $3.21 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Feb 15, 2025

Feb 15, 2025

Sarepta Therapeutics closes on $600M credit facility - TradingPedia

Feb 15, 2025

Feb 15, 2025

Sapient Capital LLC Cuts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Feb 15, 2025

Feb 14, 2025

WCM Investment Management LLC Buys 12,060 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Feb 14, 2025

Feb 14, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat

Feb 14, 2025

Feb 14, 2025

10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga

Feb 14, 2025

Feb 14, 2025

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility - Marketscreener.com

Feb 14, 2025

Feb 14, 2025

Sarepta Therapeutics Closes $600 Million Revolving Credit Facility -February 14, 2025 at 09:08 am EST - Marketscreener.com

Feb 14, 2025

Feb 14, 2025

Major Banks Back Sarepta With $600M Credit Facility: Financial Power Move Revealed - StockTitan

Feb 14, 2025

Feb 13, 2025

SRPTSarepta Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Feb 13, 2025

Feb 12, 2025

Sarepta Q4 Earnings Preview: Rare Disease Leader's Full-Year Performance Revealed - StockTitan

Feb 12, 2025

Feb 12, 2025

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Gladstone Institutional Advisory LLC - MarketBeat

Feb 12, 2025

Feb 12, 2025

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results - Business Wire

Feb 12, 2025

Feb 11, 2025

Deutsche Bank sets Sarepta stock target at $136, cites risks - MSN

Feb 11, 2025

Feb 11, 2025

Deutsche Bank Initiates Coverage on Sarepta Therapeutics With Hold Rating, $136 Price Target - Marketscreener.com

Feb 11, 2025

Feb 11, 2025

Tobam Has $3.52 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Feb 11, 2025

Feb 10, 2025

Arrowhead Secures Massive $825M Deal as FDA Fast-Tracks Breakthrough Drug - StockTitan

Feb 10, 2025

Feb 10, 2025

Arrowhead Closes Licensing, Collaboration Agreement With Sarepta -February 10, 2025 at 09:39 am EST - Marketscreener.com

Feb 10, 2025

Feb 10, 2025

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics - BioSpace

Feb 10, 2025

Feb 10, 2025

Arrowhead to receives $500M upfront in licensing pact with Sarepta - TipRanks

Feb 10, 2025

Feb 10, 2025

ARWR Seals Mega-Deal: $825M Cash Infusion Plus Billions in Potential Milestone Payments - StockTitan

Feb 10, 2025